G01N 2333/70517
Cd8
G01N2333/70517 (Cd8) appears on 125 US grants and 280 published applications in this corpus.
Search patents in G01N- Granted patents
- 125
- Published applications
- 280
- Assignees
- 183
- Inventors
- 548
- Latest grant
- 7 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 1 | 3 |
| 2005 | 0 | 2 |
| 2006 | 1 | 1 |
| 2007 | 1 | 4 |
| 2008 | 2 | 2 |
| 2009 | 1 | 6 |
| 2010 | 0 | 5 |
| 2011 | 2 | 4 |
| 2012 | 2 | 20 |
| 2013 | 1 | 3 |
| 2014 | 1 | 10 |
| 2015 | 7 | 22 |
| 2016 | 7 | 24 |
| 2017 | 6 | 18 |
| 2018 | 17 | 16 |
| 2019 | 11 | 15 |
| 2020 | 13 | 19 |
| 2021 | 10 | 16 |
| 2022 | 7 | 16 |
| 2023 | 8 | 19 |
| 2024 | 11 | 21 |
| 2025 | 11 | 22 |
| 2026 | 5 | 11 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- CD8-specific capture agents, compositions, and methods of using and making7 Apr 2026US 12,594,350 B2Regeneron Pharmaceuticals, Inc.
- TCR-independent molecular identification of mutation-related and tumor-specific T cells17 Mar 2026US 12,578,332 B2Medizinische Hochschule Hannover
- Biomarkers for determining the efficacy of immune checkpoint inhibitors10 Mar 2026US 12,571,799 B2National Cancer Center
- CD8A-binding fibronectin type III domains24 Feb 2026US 12,559,541 B2Janssen Biotech, Inc.
- Anti-CD8 alpha depleting antibodies13 Jan 2026US 12,522,659 B2Polygon Therapeutics
- Postural orthostatic tachycardia syndrome and crth224 Sep 2026US 2026/0287597 A1Amerimmune LLC
- Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy30 Jul 2026US 2026/0216331 A1Juno Therapeutics, Inc.
- Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy30 Jul 2026US 2026/0216332 A1Juno Therapeutics, Inc.
- Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy9 Jul 2026US 2026/0191959 A1Juno Therapeutics, Inc.
- CD8A-Binding Fibronectin Type III Domains9 Jul 2026US 2026/0193322 A1Janssen Biotech, Inc.
Most cited
By later US patents
- Tolerogenic synthetic nanocarriers for inducing regulatory B cells129US 8,652,487 B2Selecta Biosciences, Inc. · 2014
- Tolerogenic synthetic nanocarriers42US 9,265,815 B2Selecta Biosciences, Inc. · 2016
- Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins29US 9,295,718 B2Selecta Biosciences, Inc. · 2016
- Tolerogenic synthetic nanocarriers for allergy therapy27US 9,289,476 B2Selecta Biosciences, Inc. · 2016
- Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses27US 9,289,477 B2Selecta Biosciences, Inc. · 2016